\n
![\"EarthSnap\"\/](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/01\/earthsnap-banner-news.webp.webp\")
\n<\/a><\/p>\n
Within a controlled clinical setting, adults with long-standing, treatment-resistant obsessive-compulsive disorder received either psilocybin or an inactive comparison under close supervision.<\/p>\n
At Yale University School of Medicine<\/a>, Christopher Pittenger and colleagues documented sharp symptom reductions within 48 hours among those given psilocybin, while scores in the comparison group remained largely unchanged.<\/p>\n For many participants, this improvement held steady over the following weeks, even though no additional doses were given during that period.<\/p>\n Such durability after a single intervention raises questions about how a brief experience can produce lasting change, setting up the need to understand what shifted in the brain.<\/p>\n Visible benefits within two days<\/p>\n Within 48 hours, symptom scores fell by 9.76 points in the OCD psilocybin group while the niacin group barely moved in the trial<\/a>.<\/p>\n After one week, nine of 13 participants who received psilocybin improved by at least 35 percent.<\/p>\n The benefits remained visible through the full follow-up for most of the people who responded after that first dose.<\/p>\n Speed is the striking part, because standard OCD drugs usually take weeks before relief starts to appear.<\/p>\n Why speed matters<\/p>\n Obsessive-compulsive disorder affects roughly 2 two to three percent of people and often begins early, as a large survey<\/a> found.<\/p>\n Even after therapy and medication, 40 to 60 percent keep clinically important symptoms, a stubborn pattern summarized in a major review<\/a>.<\/p>\n For people in the Yale psilocybin trial, OCD had already consumed about two decades, which makes a fast response especially unusual.<\/p>\n That history explains why researchers see this result less as a tweak and more as a different treatment model.<\/p>\n How the session worked<\/p>\n The participants took psilocybin \u2013 the psychedelic compound in magic mushrooms \u2013 with eyeshades, music, and two facilitators nearby.<\/p>\n Preparation and follow-up sessions gave people room to steady themselves and describe what surfaced, following the published protocol<\/a>.<\/p>\n \u201cIt\u2019s pretty intense, though it varies from person to person,\u201d said Pittenger, describing the supervised dosing experience.<\/p>\n That intensity may help loosen fixed habits, but it also explains why the drug was given with careful monitoring.<\/p>\n Flexible communication in the brain<\/p>\n Researchers suspect the drug briefly boosts neuroplasticity<\/a>, the brain\u2019s ability to rewire connections, after patterns have become rigid.<\/p>\n Animal work has linked psychedelics to new branches and connections in nerve cells, a line of evidence<\/a>.<\/p>\n Another idea centers on the default mode network, a system tied to self-focused thought, which may stop dominating the brain.<\/p>\n Brain scans after psilocybin in depression have shown more flexible communication across networks, a pattern that fits this theory<\/a>.<\/p>\n Side effects and safety<\/p>\n Most of the side effects were short-lived and mild, including nausea, anxiety, headache, and visual changes during the dosing day.<\/p>\n One participant with long-standing suicidal thoughts began planning suicide after dosing, and then improved within 72 hours under standard monitoring.<\/p>\n That serious event did not lead to a death, but it showed why clinics cannot treat this like routine prescribing.<\/p>\n Outside of medical settings, the same experience could become far harder to manage safely for someone who is already vulnerable.<\/p>\n Psilocybin for OCD treatment <\/p>\n Unlike daily medication<\/a>, this approach aims for a large interruption in symptoms after one supervised session rather than gradual accumulation.<\/p>\n Function improved too, with disability scores dropping 42 percent across follow-up in the psilocybin group.<\/p>\n Mood scores also improved, hinting that the dose may calm more than compulsions when distress and depression travel together.<\/p>\n That broader relief could matter in real life, where OCD rarely arrives without exhaustion, shame, or lost time.<\/p>\n Future research directions <\/p>\n Larger trials now need to show whether the same gains hold across broader groups, longer follow-up, and more clinics.<\/p>\n Researchers also need clearer rules for screening risk, choosing dose, and deciding who may need more than one session.<\/p>\n Another open question is whether some patients need only one session while others may need planned repeats.<\/p>\n Answers like those will decide whether clinics treat psilocybin<\/a> as a rescue option or a broader tool.<\/p>\n For people trapped in rituals after years of failed care, one monitored psychedelic session produced relief that appeared fast and lasted months.<\/p>\n Whether that becomes routine treatment will depend on bigger trials, tighter safety systems, and proof that the result survives tougher testing.<\/p>\n The study is published as a preprint in The Lancet<\/a>.<\/p>\n \u2014\u2013<\/p>\n Like what you read? Subscribe to our newsletter<\/a> for engaging articles, exclusive content, and the latest updates.<\/p>\n Check us out on EarthSnap<\/a>, a free app brought to you by Eric Ralls<\/a> and Earth.com.<\/p>\n \u2014\u2013<\/p>\n","protected":false},"excerpt":{"rendered":"Researchers have found that a single dose of psilocybin rapidly reduces symptoms of obsessive-compulsive disorder (OCD) in patients…\n","protected":false},"author":2,"featured_media":353053,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,111,139,69],"class_list":{"0":"post-353431","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-health","9":"tag-new-zealand","10":"tag-newzealand","11":"tag-nz"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/353431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=353431"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/353431\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/353053"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=353431"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=353431"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=353431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}